View
/ Download pdf version of this article
Question: 1 2 3 4
5 6 7 8
1. In which of the following situations would testing troponin levels be useful? |
Your peers |
GP Panel |
To confirm a suspicious ECG |
27% |
|
Use to rule out MI, in someone presenting with acute chest pain |
13% |
|
Screening for people with high cardiovascular risk |
0% |
|
Delayed presentation of suspected MI |
97% |
|
Comment:
Almost all of GPs correctly responded that one of the key situations in which troponin is useful in primary care, is
for patients presenting 24–72 hours after a single episode of chest pain e.g. the “Monday morning” consultation.
Measurement of troponin and ECG will establish whether or not the chest pain was due to a MI. If there has been a MI,
troponin is likely to remain elevated for up to 10 days. A positive troponin result is indication for immediate referral.
The use of troponin to confirm a suspicious ECG or to rule out an MI in someone presenting with acute chest pain is not
recommended. These patients should be referred immediately to secondary care.
2. For a patient presenting a few days after a single episode of chest pain, how can troponin be
helpful? |
Your peers |
GP Panel |
To establish if chest pain was due to MI, or other causes |
94% |
|
Help determine risk of future events |
3% |
|
For someone with atypical symptoms |
81% |
|
If no ECG changes |
79% |
|
Comment:
The majority of GPs correctly identified that troponin is most helpful when there is delayed presentation, absence of
ECG changes or the presence of atypical symptoms. In these situations, troponin can provide reassurance that no MI has
occurred, or provide sufficient evidence to refer the patient to hospital.
3. Which of the following are true about the use of troponin as a screening test? |
Your peers |
GP Panel |
Can provide additional information than just lipids and glucose for CVD risk assessment |
1% |
|
Troponin is being requested more frequently as a screening test |
24% |
|
Troponin testing is only indicated if there is some suspicion of MI |
69% |
|
There is no rationale for using troponin as a screening test |
90% |
|
Comment:
There has been some concern expressed by Cardiologists that troponin may be being used for CVD risk assessments in primary
care. However the responses to this question indicate general practitioners are well aware troponin does not provide any
additional information for CVD risk assessment and that there is no indication for troponin testing in asymptomatic patients.
4. A negative troponin can only be used as a rule out test if it is: |
Your peers |
GP Panel |
Laboratory measured |
59% |
|
From a point-of-care analyser |
2% |
|
Negative 4 hours post onset symptoms |
3% |
|
Negative 10 hours post onset symptoms |
96% |
|
Comment:
Most respondents correctly identified that a negative troponin result is an appropriate “rule out” test
for MI. But fewer recognised that a laboratory method must be used if the initial symptoms occurred more than 10 hours
ago. Most point-of-care methods for troponin testing do not have sufficient sensitivity to “rule out” acute
MI.
What is the appropriate action following a positive troponin test? |
Your peers |
GP Panel |
Immediate referral to secondary care |
99% |
|
Confirm with ECG |
3% |
|
Perform repeat troponin test in 4 hours |
2% |
|
A positive troponin from a point-of-care analyser, should be confirmed with a laboratory tested
specimen |
11% |
|
Comment:
A positive result for troponin, whether from the laboratory or from a point-of-care analyser, is significant and the
patient should be referred immediately to secondary care. This should not be delayed by repeating the test (either by
point-of-care or in the laboratory) or by confirming with ECG.
6. Which of the following are true about the interpretation of a troponin test? |
Your peers |
GP Panel |
A negative troponin at the time of presentation is a useful rule out test |
5% |
|
It takes 3–4 hours for troponin levels to begin to rise |
86% |
|
Troponin is useful for a delayed presentation, since troponins can remain elevated for up to 2
weeks |
81% |
|
In patient with no ST changes, but elevated troponin, it is worth considering other causes |
48% |
|
Comment:
A patient with no ST changes but elevated troponin should be assumed to have had a MI and referred immediately to secondary
care. There may be rare circumstances in which the troponin is elevated for a reason other than MI but it is not appropriate
to delay referral.
7. Which of the following are true about the use of urea as a ‘renal function test’? |
Your peers |
GP Panel |
Has been superseded by eGFR and creatinine |
96% |
|
Is generally an insensitive marker of renal failure |
75% |
|
Urea levels can be altered by a number of non-renal causes |
95% |
|
Urea:creatinine ratio remains a useful means of distinguishing between pre-renal and renal causes
of renal failure |
4% |
|
Comment:
Urea is generally an insensitive marker of renal failure as levels can vary for a number of reasons such as high/low
protein diet, tissue breakdown, GI haemorrhage and liver disease. Note: using the urea:creatinine ratio to distinguish
between pre-renal and renal causes is now considered unreliable; eGFR and creatinine are preferred instead.
8. Indicate the situations where urea may have a role: |
Your peers |
GP Panel |
Management of a patient on dialysis |
94% |
|
Occasionally for the assessment of dehydration in the frail elderly |
89% |
|
Monitoring changes in renal function for people on ACE-inhibitors or diuretics |
1% |
|
For areas of New Zealand that do not calculate eGFR |
6% |
|
Comment:
Urea has a limited role in primary care, although it may be useful in some circumstances for assessing hydration status
in frail elderly.
eGFR is now routinely reported by all laboratories throughout New Zealand, when creatinine is requested.